Global Immune Checkpoint Agents Market Growth 2025-2031
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Immune Checkpoint Agents market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Immune Checkpoint Agents are a class of drugs used in cancer treatment that help the body fight cancer cells by modulating the function of the immune system. Immune checkpoints are biological mechanisms that help maintain the balance of the immune system and prevent it from attacking normal cells. However, some cancer cells can use this mechanism to evade immune system attack.
United States market for Immune Checkpoint Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Immune Checkpoint Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Immune Checkpoint Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Immune Checkpoint Agents players cover Bristol Myers Squibb, Merck, AstraZeneca, Roche, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Immune Checkpoint Agents Industry Forecast” looks at past sales and reviews total world Immune Checkpoint Agents sales in 2024, providing a comprehensive analysis by region and market sector of projected Immune Checkpoint Agents sales for 2025 through 2031. With Immune Checkpoint Agents sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immune Checkpoint Agents industry.
This Insight Report provides a comprehensive analysis of the global Immune Checkpoint Agents landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Immune Checkpoint Agents portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Immune Checkpoint Agents market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immune Checkpoint Agents and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immune Checkpoint Agents.
This report presents a comprehensive overview, market shares, and growth opportunities of Immune Checkpoint Agents market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Immune Checkpoint Agents market?
What factors are driving Immune Checkpoint Agents market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Immune Checkpoint Agents market opportunities vary by end market size?
How does Immune Checkpoint Agents break out by Type, by Application?
The global Immune Checkpoint Agents market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Immune Checkpoint Agents are a class of drugs used in cancer treatment that help the body fight cancer cells by modulating the function of the immune system. Immune checkpoints are biological mechanisms that help maintain the balance of the immune system and prevent it from attacking normal cells. However, some cancer cells can use this mechanism to evade immune system attack.
United States market for Immune Checkpoint Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Immune Checkpoint Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Immune Checkpoint Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Immune Checkpoint Agents players cover Bristol Myers Squibb, Merck, AstraZeneca, Roche, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Immune Checkpoint Agents Industry Forecast” looks at past sales and reviews total world Immune Checkpoint Agents sales in 2024, providing a comprehensive analysis by region and market sector of projected Immune Checkpoint Agents sales for 2025 through 2031. With Immune Checkpoint Agents sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immune Checkpoint Agents industry.
This Insight Report provides a comprehensive analysis of the global Immune Checkpoint Agents landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Immune Checkpoint Agents portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Immune Checkpoint Agents market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immune Checkpoint Agents and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immune Checkpoint Agents.
This report presents a comprehensive overview, market shares, and growth opportunities of Immune Checkpoint Agents market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Anti-PD-L1 Drug
- Anti-PD-1 Drug
- CTLA4
- Lung Cancer
- Colorectal Cancer
- BreastCancer
- Prostate Cancer
- Melanoma
- Blood Cancers
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Bristol Myers Squibb
- Merck
- AstraZeneca
- Roche
What is the 10-year outlook for the global Immune Checkpoint Agents market?
What factors are driving Immune Checkpoint Agents market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Immune Checkpoint Agents market opportunities vary by end market size?
How does Immune Checkpoint Agents break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Immune Checkpoint Agents Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Immune Checkpoint Agents by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Immune Checkpoint Agents by Country/Region, 2020, 2024 & 2031
2.2 Immune Checkpoint Agents Segment by Type
2.2.1 Anti-PD-L1 Drug
2.2.2 Anti-PD-1 Drug
2.2.3 CTLA4
2.3 Immune Checkpoint Agents Sales by Type
2.3.1 Global Immune Checkpoint Agents Sales Market Share by Type (2020-2025)
2.3.2 Global Immune Checkpoint Agents Revenue and Market Share by Type (2020-2025)
2.3.3 Global Immune Checkpoint Agents Sale Price by Type (2020-2025)
2.4 Immune Checkpoint Agents Segment by Application
2.4.1 Lung Cancer
2.4.2 Colorectal Cancer
2.4.3 BreastCancer
2.4.4 Prostate Cancer
2.4.5 Melanoma
2.4.6 Blood Cancers
2.5 Immune Checkpoint Agents Sales by Application
2.5.1 Global Immune Checkpoint Agents Sale Market Share by Application (2020-2025)
2.5.2 Global Immune Checkpoint Agents Revenue and Market Share by Application (2020-2025)
2.5.3 Global Immune Checkpoint Agents Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Immune Checkpoint Agents Breakdown Data by Company
3.1.1 Global Immune Checkpoint Agents Annual Sales by Company (2020-2025)
3.1.2 Global Immune Checkpoint Agents Sales Market Share by Company (2020-2025)
3.2 Global Immune Checkpoint Agents Annual Revenue by Company (2020-2025)
3.2.1 Global Immune Checkpoint Agents Revenue by Company (2020-2025)
3.2.2 Global Immune Checkpoint Agents Revenue Market Share by Company (2020-2025)
3.3 Global Immune Checkpoint Agents Sale Price by Company
3.4 Key Manufacturers Immune Checkpoint Agents Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Immune Checkpoint Agents Product Location Distribution
3.4.2 Players Immune Checkpoint Agents Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR IMMUNE CHECKPOINT AGENTS BY GEOGRAPHIC REGION
4.1 World Historic Immune Checkpoint Agents Market Size by Geographic Region (2020-2025)
4.1.1 Global Immune Checkpoint Agents Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Immune Checkpoint Agents Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Immune Checkpoint Agents Market Size by Country/Region (2020-2025)
4.2.1 Global Immune Checkpoint Agents Annual Sales by Country/Region (2020-2025)
4.2.2 Global Immune Checkpoint Agents Annual Revenue by Country/Region (2020-2025)
4.3 Americas Immune Checkpoint Agents Sales Growth
4.4 APAC Immune Checkpoint Agents Sales Growth
4.5 Europe Immune Checkpoint Agents Sales Growth
4.6 Middle East & Africa Immune Checkpoint Agents Sales Growth
5 AMERICAS
5.1 Americas Immune Checkpoint Agents Sales by Country
5.1.1 Americas Immune Checkpoint Agents Sales by Country (2020-2025)
5.1.2 Americas Immune Checkpoint Agents Revenue by Country (2020-2025)
5.2 Americas Immune Checkpoint Agents Sales by Type (2020-2025)
5.3 Americas Immune Checkpoint Agents Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immune Checkpoint Agents Sales by Region
6.1.1 APAC Immune Checkpoint Agents Sales by Region (2020-2025)
6.1.2 APAC Immune Checkpoint Agents Revenue by Region (2020-2025)
6.2 APAC Immune Checkpoint Agents Sales by Type (2020-2025)
6.3 APAC Immune Checkpoint Agents Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Immune Checkpoint Agents by Country
7.1.1 Europe Immune Checkpoint Agents Sales by Country (2020-2025)
7.1.2 Europe Immune Checkpoint Agents Revenue by Country (2020-2025)
7.2 Europe Immune Checkpoint Agents Sales by Type (2020-2025)
7.3 Europe Immune Checkpoint Agents Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Immune Checkpoint Agents by Country
8.1.1 Middle East & Africa Immune Checkpoint Agents Sales by Country (2020-2025)
8.1.2 Middle East & Africa Immune Checkpoint Agents Revenue by Country (2020-2025)
8.2 Middle East & Africa Immune Checkpoint Agents Sales by Type (2020-2025)
8.3 Middle East & Africa Immune Checkpoint Agents Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Immune Checkpoint Agents
10.3 Manufacturing Process Analysis of Immune Checkpoint Agents
10.4 Industry Chain Structure of Immune Checkpoint Agents
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Immune Checkpoint Agents Distributors
11.3 Immune Checkpoint Agents Customer
12 WORLD FORECAST REVIEW FOR IMMUNE CHECKPOINT AGENTS BY GEOGRAPHIC REGION
12.1 Global Immune Checkpoint Agents Market Size Forecast by Region
12.1.1 Global Immune Checkpoint Agents Forecast by Region (2026-2031)
12.1.2 Global Immune Checkpoint Agents Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Immune Checkpoint Agents Forecast by Type (2026-2031)
12.7 Global Immune Checkpoint Agents Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Bristol Myers Squibb
13.1.1 Bristol Myers Squibb Company Information
13.1.2 Bristol Myers Squibb Immune Checkpoint Agents Product Portfolios and Specifications
13.1.3 Bristol Myers Squibb Immune Checkpoint Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Bristol Myers Squibb Main Business Overview
13.1.5 Bristol Myers Squibb Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Immune Checkpoint Agents Product Portfolios and Specifications
13.2.3 Merck Immune Checkpoint Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 AstraZeneca
13.3.1 AstraZeneca Company Information
13.3.2 AstraZeneca Immune Checkpoint Agents Product Portfolios and Specifications
13.3.3 AstraZeneca Immune Checkpoint Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 AstraZeneca Main Business Overview
13.3.5 AstraZeneca Latest Developments
13.4 Roche
13.4.1 Roche Company Information
13.4.2 Roche Immune Checkpoint Agents Product Portfolios and Specifications
13.4.3 Roche Immune Checkpoint Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Roche Main Business Overview
13.4.5 Roche Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Immune Checkpoint Agents Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Immune Checkpoint Agents Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Anti-PD-L1 Drug
Table 4. Major Players of Anti-PD-1 Drug
Table 5. Major Players of CTLA4
Table 6. Global Immune Checkpoint Agents Sales byType (2020-2025) & (K Units)
Table 7. Global Immune Checkpoint Agents Sales Market Share byType (2020-2025)
Table 8. Global Immune Checkpoint Agents Revenue byType (2020-2025) & ($ million)
Table 9. Global Immune Checkpoint Agents Revenue Market Share byType (2020-2025)
Table 10. Global Immune Checkpoint Agents Sale Price byType (2020-2025) & (USD/Unit)
Table 11. Global Immune Checkpoint Agents Sale by Application (2020-2025) & (K Units)
Table 12. Global Immune Checkpoint Agents Sale Market Share by Application (2020-2025)
Table 13. Global Immune Checkpoint Agents Revenue by Application (2020-2025) & ($ million)
Table 14. Global Immune Checkpoint Agents Revenue Market Share by Application (2020-2025)
Table 15. Global Immune Checkpoint Agents Sale Price by Application (2020-2025) & (USD/Unit)
Table 16. Global Immune Checkpoint Agents Sales by Company (2020-2025) & (K Units)
Table 17. Global Immune Checkpoint Agents Sales Market Share by Company (2020-2025)
Table 18. Global Immune Checkpoint Agents Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Immune Checkpoint Agents Revenue Market Share by Company (2020-2025)
Table 20. Global Immune Checkpoint Agents Sale Price by Company (2020-2025) & (USD/Unit)
Table 21. Key Manufacturers Immune Checkpoint Agents Producing Area Distribution and Sales Area
Table 22. Players Immune Checkpoint Agents Products Offered
Table 23. Immune Checkpoint Agents Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Immune Checkpoint Agents Sales by Geographic Region (2020-2025) & (K Units)
Table 27. Global Immune Checkpoint Agents Sales Market Share Geographic Region (2020-2025)
Table 28. Global Immune Checkpoint Agents Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Immune Checkpoint Agents Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Immune Checkpoint Agents Sales by Country/Region (2020-2025) & (K Units)
Table 31. Global Immune Checkpoint Agents Sales Market Share by Country/Region (2020-2025)
Table 32. Global Immune Checkpoint Agents Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Immune Checkpoint Agents Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Immune Checkpoint Agents Sales by Country (2020-2025) & (K Units)
Table 35. Americas Immune Checkpoint Agents Sales Market Share by Country (2020-2025)
Table 36. Americas Immune Checkpoint Agents Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Immune Checkpoint Agents Sales byType (2020-2025) & (K Units)
Table 38. Americas Immune Checkpoint Agents Sales by Application (2020-2025) & (K Units)
Table 39. APAC Immune Checkpoint Agents Sales by Region (2020-2025) & (K Units)
Table 40. APAC Immune Checkpoint Agents Sales Market Share by Region (2020-2025)
Table 41. APAC Immune Checkpoint Agents Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Immune Checkpoint Agents Sales byType (2020-2025) & (K Units)
Table 43. APAC Immune Checkpoint Agents Sales by Application (2020-2025) & (K Units)
Table 44. Europe Immune Checkpoint Agents Sales by Country (2020-2025) & (K Units)
Table 45. Europe Immune Checkpoint Agents Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Immune Checkpoint Agents Sales byType (2020-2025) & (K Units)
Table 47. Europe Immune Checkpoint Agents Sales by Application (2020-2025) & (K Units)
Table 48. Middle East & Africa Immune Checkpoint Agents Sales by Country (2020-2025) & (K Units)
Table 49. Middle East & Africa Immune Checkpoint Agents Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Immune Checkpoint Agents Sales byType (2020-2025) & (K Units)
Table 51. Middle East & Africa Immune Checkpoint Agents Sales by Application (2020-2025) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Immune Checkpoint Agents
Table 53. Key Market Challenges & Risks of Immune Checkpoint Agents
Table 54. Key IndustryTrends of Immune Checkpoint Agents
Table 55. Immune Checkpoint Agents Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Immune Checkpoint Agents Distributors List
Table 58. Immune Checkpoint Agents Customer List
Table 59. Global Immune Checkpoint Agents SalesForecast by Region (2026-2031) & (K Units)
Table 60. Global Immune Checkpoint Agents RevenueForecast by Region (2026-2031) & ($ millions)
Table 61. Americas Immune Checkpoint Agents SalesForecast by Country (2026-2031) & (K Units)
Table 62. Americas Immune Checkpoint Agents Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 63. APAC Immune Checkpoint Agents SalesForecast by Region (2026-2031) & (K Units)
Table 64. APAC Immune Checkpoint Agents Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 65. Europe Immune Checkpoint Agents SalesForecast by Country (2026-2031) & (K Units)
Table 66. Europe Immune Checkpoint Agents RevenueForecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Immune Checkpoint Agents SalesForecast by Country (2026-2031) & (K Units)
Table 68. Middle East & Africa Immune Checkpoint Agents RevenueForecast by Country (2026-2031) & ($ millions)
Table 69. Global Immune Checkpoint Agents SalesForecast byType (2026-2031) & (K Units)
Table 70. Global Immune Checkpoint Agents RevenueForecast byType (2026-2031) & ($ millions)
Table 71. Global Immune Checkpoint Agents SalesForecast by Application (2026-2031) & (K Units)
Table 72. Global Immune Checkpoint Agents RevenueForecast by Application (2026-2031) & ($ millions)
Table 73. Bristol Myers Squibb Basic Information, Immune Checkpoint Agents Manufacturing Base, Sales Area and Its Competitors
Table 74. Bristol Myers Squibb Immune Checkpoint Agents Product Portfolios and Specifications
Table 75. Bristol Myers Squibb Immune Checkpoint Agents Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 76. Bristol Myers Squibb Main Business
Table 77. Bristol Myers Squibb Latest Developments
Table 78. Merck Basic Information, Immune Checkpoint Agents Manufacturing Base, Sales Area and Its Competitors
Table 79. Merck Immune Checkpoint Agents Product Portfolios and Specifications
Table 80. Merck Immune Checkpoint Agents Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 81. Merck Main Business
Table 82. Merck Latest Developments
Table 83. AstraZeneca Basic Information, Immune Checkpoint Agents Manufacturing Base, Sales Area and Its Competitors
Table 84. AstraZeneca Immune Checkpoint Agents Product Portfolios and Specifications
Table 85. AstraZeneca Immune Checkpoint Agents Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 86. AstraZeneca Main Business
Table 87. AstraZeneca Latest Developments
Table 88. Roche Basic Information, Immune Checkpoint Agents Manufacturing Base, Sales Area and Its Competitors
Table 89. Roche Immune Checkpoint Agents Product Portfolios and Specifications
Table 90. Roche Immune Checkpoint Agents Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 91. Roche Main Business
Table 92. Roche Latest Developments
LIST OFFIGURES
Figure 1. Picture of Immune Checkpoint Agents
Figure 2. Immune Checkpoint Agents Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Immune Checkpoint Agents Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Immune Checkpoint Agents Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Immune Checkpoint Agents Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Immune Checkpoint Agents Sales Market Share by Country/Region (2024)
Figure 10. Immune Checkpoint Agents Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Anti-PD-L1 Drug
Figure 12. Product Picture of Anti-PD-1 Drug
Figure 13. Product Picture of CTLA4
Figure 14. Global Immune Checkpoint Agents Sales Market Share byType in 2025
Figure 15. Global Immune Checkpoint Agents Revenue Market Share byType (2020-2025)
Figure 16. Immune Checkpoint Agents Consumed in Lung Cancer
Figure 17. Global Immune Checkpoint Agents Market: Lung Cancer (2020-2025) & (K Units)
Figure 18. Immune Checkpoint Agents Consumed in Colorectal Cancer
Figure 19. Global Immune Checkpoint Agents Market: Colorectal Cancer (2020-2025) & (K Units)
Figure 20. Immune Checkpoint Agents Consumed in BreastCancer
Figure 21. Global Immune Checkpoint Agents Market: BreastCancer (2020-2025) & (K Units)
Figure 22. Immune Checkpoint Agents Consumed in Prostate Cancer
Figure 23. Global Immune Checkpoint Agents Market: Prostate Cancer (2020-2025) & (K Units)
Figure 24. Immune Checkpoint Agents Consumed in Melanoma
Figure 25. Global Immune Checkpoint Agents Market: Melanoma (2020-2025) & (K Units)
Figure 26. Immune Checkpoint Agents Consumed in Blood Cancers
Figure 27. Global Immune Checkpoint Agents Market: Blood Cancers (2020-2025) & (K Units)
Figure 28. Global Immune Checkpoint Agents Sale Market Share by Application (2024)
Figure 29. Global Immune Checkpoint Agents Revenue Market Share by Application in 2025
Figure 30. Immune Checkpoint Agents Sales by Company in 2025 (K Units)
Figure 31. Global Immune Checkpoint Agents Sales Market Share by Company in 2025
Figure 32. Immune Checkpoint Agents Revenue by Company in 2025 ($ millions)
Figure 33. Global Immune Checkpoint Agents Revenue Market Share by Company in 2025
Figure 34. Global Immune Checkpoint Agents Sales Market Share by Geographic Region (2020-2025)
Figure 35. Global Immune Checkpoint Agents Revenue Market Share by Geographic Region in 2025
Figure 36. Americas Immune Checkpoint Agents Sales 2020-2025 (K Units)
Figure 37. Americas Immune Checkpoint Agents Revenue 2020-2025 ($ millions)
Figure 38. APAC Immune Checkpoint Agents Sales 2020-2025 (K Units)
Figure 39. APAC Immune Checkpoint Agents Revenue 2020-2025 ($ millions)
Figure 40. Europe Immune Checkpoint Agents Sales 2020-2025 (K Units)
Figure 41. Europe Immune Checkpoint Agents Revenue 2020-2025 ($ millions)
Figure 42. Middle East & Africa Immune Checkpoint Agents Sales 2020-2025 (K Units)
Figure 43. Middle East & Africa Immune Checkpoint Agents Revenue 2020-2025 ($ millions)
Figure 44. Americas Immune Checkpoint Agents Sales Market Share by Country in 2025
Figure 45. Americas Immune Checkpoint Agents Revenue Market Share by Country (2020-2025)
Figure 46. Americas Immune Checkpoint Agents Sales Market Share byType (2020-2025)
Figure 47. Americas Immune Checkpoint Agents Sales Market Share by Application (2020-2025)
Figure 48. United States Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 49. Canada Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 50. Mexico Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 51. Brazil Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 52. APAC Immune Checkpoint Agents Sales Market Share by Region in 2025
Figure 53. APAC Immune Checkpoint Agents Revenue Market Share by Region (2020-2025)
Figure 54. APAC Immune Checkpoint Agents Sales Market Share byType (2020-2025)
Figure 55. APAC Immune Checkpoint Agents Sales Market Share by Application (2020-2025)
Figure 56. China Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 57. Japan Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 58. South Korea Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 59. Southeast Asia Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 60. India Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 61. Australia Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 62. ChinaTaiwan Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 63. Europe Immune Checkpoint Agents Sales Market Share by Country in 2025
Figure 64. Europe Immune Checkpoint Agents Revenue Market Share by Country (2020-2025)
Figure 65. Europe Immune Checkpoint Agents Sales Market Share byType (2020-2025)
Figure 66. Europe Immune Checkpoint Agents Sales Market Share by Application (2020-2025)
Figure 67. Germany Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 68.France Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 69. UK Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 70. Italy Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 71. Russia Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 72. Middle East & Africa Immune Checkpoint Agents Sales Market Share by Country (2020-2025)
Figure 73. Middle East & Africa Immune Checkpoint Agents Sales Market Share byType (2020-2025)
Figure 74. Middle East & Africa Immune Checkpoint Agents Sales Market Share by Application (2020-2025)
Figure 75. Egypt Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 76. South Africa Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 77. Israel Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 78.Turkey Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 79. GCC Countries Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 80. Manufacturing Cost Structure Analysis of Immune Checkpoint Agents in 2025
Figure 81. Manufacturing Process Analysis of Immune Checkpoint Agents
Figure 82. Industry Chain Structure of Immune Checkpoint Agents
Figure 83. Channels of Distribution
Figure 84. Global Immune Checkpoint Agents Sales MarketForecast by Region (2026-2031)
Figure 85. Global Immune Checkpoint Agents Revenue Market ShareForecast by Region (2026-2031)
Figure 86. Global Immune Checkpoint Agents Sales Market ShareForecast byType (2026-2031)
Figure 87. Global Immune Checkpoint Agents Revenue Market ShareForecast byType (2026-2031)
Figure 88. Global Immune Checkpoint Agents Sales Market ShareForecast by Application (2026-2031)
Figure 89. Global Immune Checkpoint Agents Revenue Market ShareForecast by Application (2026-2031)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Immune Checkpoint Agents Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Immune Checkpoint Agents by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Immune Checkpoint Agents by Country/Region, 2020, 2024 & 2031
2.2 Immune Checkpoint Agents Segment by Type
2.2.1 Anti-PD-L1 Drug
2.2.2 Anti-PD-1 Drug
2.2.3 CTLA4
2.3 Immune Checkpoint Agents Sales by Type
2.3.1 Global Immune Checkpoint Agents Sales Market Share by Type (2020-2025)
2.3.2 Global Immune Checkpoint Agents Revenue and Market Share by Type (2020-2025)
2.3.3 Global Immune Checkpoint Agents Sale Price by Type (2020-2025)
2.4 Immune Checkpoint Agents Segment by Application
2.4.1 Lung Cancer
2.4.2 Colorectal Cancer
2.4.3 BreastCancer
2.4.4 Prostate Cancer
2.4.5 Melanoma
2.4.6 Blood Cancers
2.5 Immune Checkpoint Agents Sales by Application
2.5.1 Global Immune Checkpoint Agents Sale Market Share by Application (2020-2025)
2.5.2 Global Immune Checkpoint Agents Revenue and Market Share by Application (2020-2025)
2.5.3 Global Immune Checkpoint Agents Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Immune Checkpoint Agents Breakdown Data by Company
3.1.1 Global Immune Checkpoint Agents Annual Sales by Company (2020-2025)
3.1.2 Global Immune Checkpoint Agents Sales Market Share by Company (2020-2025)
3.2 Global Immune Checkpoint Agents Annual Revenue by Company (2020-2025)
3.2.1 Global Immune Checkpoint Agents Revenue by Company (2020-2025)
3.2.2 Global Immune Checkpoint Agents Revenue Market Share by Company (2020-2025)
3.3 Global Immune Checkpoint Agents Sale Price by Company
3.4 Key Manufacturers Immune Checkpoint Agents Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Immune Checkpoint Agents Product Location Distribution
3.4.2 Players Immune Checkpoint Agents Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR IMMUNE CHECKPOINT AGENTS BY GEOGRAPHIC REGION
4.1 World Historic Immune Checkpoint Agents Market Size by Geographic Region (2020-2025)
4.1.1 Global Immune Checkpoint Agents Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Immune Checkpoint Agents Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Immune Checkpoint Agents Market Size by Country/Region (2020-2025)
4.2.1 Global Immune Checkpoint Agents Annual Sales by Country/Region (2020-2025)
4.2.2 Global Immune Checkpoint Agents Annual Revenue by Country/Region (2020-2025)
4.3 Americas Immune Checkpoint Agents Sales Growth
4.4 APAC Immune Checkpoint Agents Sales Growth
4.5 Europe Immune Checkpoint Agents Sales Growth
4.6 Middle East & Africa Immune Checkpoint Agents Sales Growth
5 AMERICAS
5.1 Americas Immune Checkpoint Agents Sales by Country
5.1.1 Americas Immune Checkpoint Agents Sales by Country (2020-2025)
5.1.2 Americas Immune Checkpoint Agents Revenue by Country (2020-2025)
5.2 Americas Immune Checkpoint Agents Sales by Type (2020-2025)
5.3 Americas Immune Checkpoint Agents Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immune Checkpoint Agents Sales by Region
6.1.1 APAC Immune Checkpoint Agents Sales by Region (2020-2025)
6.1.2 APAC Immune Checkpoint Agents Revenue by Region (2020-2025)
6.2 APAC Immune Checkpoint Agents Sales by Type (2020-2025)
6.3 APAC Immune Checkpoint Agents Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Immune Checkpoint Agents by Country
7.1.1 Europe Immune Checkpoint Agents Sales by Country (2020-2025)
7.1.2 Europe Immune Checkpoint Agents Revenue by Country (2020-2025)
7.2 Europe Immune Checkpoint Agents Sales by Type (2020-2025)
7.3 Europe Immune Checkpoint Agents Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Immune Checkpoint Agents by Country
8.1.1 Middle East & Africa Immune Checkpoint Agents Sales by Country (2020-2025)
8.1.2 Middle East & Africa Immune Checkpoint Agents Revenue by Country (2020-2025)
8.2 Middle East & Africa Immune Checkpoint Agents Sales by Type (2020-2025)
8.3 Middle East & Africa Immune Checkpoint Agents Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Immune Checkpoint Agents
10.3 Manufacturing Process Analysis of Immune Checkpoint Agents
10.4 Industry Chain Structure of Immune Checkpoint Agents
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Immune Checkpoint Agents Distributors
11.3 Immune Checkpoint Agents Customer
12 WORLD FORECAST REVIEW FOR IMMUNE CHECKPOINT AGENTS BY GEOGRAPHIC REGION
12.1 Global Immune Checkpoint Agents Market Size Forecast by Region
12.1.1 Global Immune Checkpoint Agents Forecast by Region (2026-2031)
12.1.2 Global Immune Checkpoint Agents Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Immune Checkpoint Agents Forecast by Type (2026-2031)
12.7 Global Immune Checkpoint Agents Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Bristol Myers Squibb
13.1.1 Bristol Myers Squibb Company Information
13.1.2 Bristol Myers Squibb Immune Checkpoint Agents Product Portfolios and Specifications
13.1.3 Bristol Myers Squibb Immune Checkpoint Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Bristol Myers Squibb Main Business Overview
13.1.5 Bristol Myers Squibb Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Immune Checkpoint Agents Product Portfolios and Specifications
13.2.3 Merck Immune Checkpoint Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 AstraZeneca
13.3.1 AstraZeneca Company Information
13.3.2 AstraZeneca Immune Checkpoint Agents Product Portfolios and Specifications
13.3.3 AstraZeneca Immune Checkpoint Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 AstraZeneca Main Business Overview
13.3.5 AstraZeneca Latest Developments
13.4 Roche
13.4.1 Roche Company Information
13.4.2 Roche Immune Checkpoint Agents Product Portfolios and Specifications
13.4.3 Roche Immune Checkpoint Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Roche Main Business Overview
13.4.5 Roche Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Immune Checkpoint Agents Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Immune Checkpoint Agents Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Anti-PD-L1 Drug
Table 4. Major Players of Anti-PD-1 Drug
Table 5. Major Players of CTLA4
Table 6. Global Immune Checkpoint Agents Sales byType (2020-2025) & (K Units)
Table 7. Global Immune Checkpoint Agents Sales Market Share byType (2020-2025)
Table 8. Global Immune Checkpoint Agents Revenue byType (2020-2025) & ($ million)
Table 9. Global Immune Checkpoint Agents Revenue Market Share byType (2020-2025)
Table 10. Global Immune Checkpoint Agents Sale Price byType (2020-2025) & (USD/Unit)
Table 11. Global Immune Checkpoint Agents Sale by Application (2020-2025) & (K Units)
Table 12. Global Immune Checkpoint Agents Sale Market Share by Application (2020-2025)
Table 13. Global Immune Checkpoint Agents Revenue by Application (2020-2025) & ($ million)
Table 14. Global Immune Checkpoint Agents Revenue Market Share by Application (2020-2025)
Table 15. Global Immune Checkpoint Agents Sale Price by Application (2020-2025) & (USD/Unit)
Table 16. Global Immune Checkpoint Agents Sales by Company (2020-2025) & (K Units)
Table 17. Global Immune Checkpoint Agents Sales Market Share by Company (2020-2025)
Table 18. Global Immune Checkpoint Agents Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Immune Checkpoint Agents Revenue Market Share by Company (2020-2025)
Table 20. Global Immune Checkpoint Agents Sale Price by Company (2020-2025) & (USD/Unit)
Table 21. Key Manufacturers Immune Checkpoint Agents Producing Area Distribution and Sales Area
Table 22. Players Immune Checkpoint Agents Products Offered
Table 23. Immune Checkpoint Agents Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Immune Checkpoint Agents Sales by Geographic Region (2020-2025) & (K Units)
Table 27. Global Immune Checkpoint Agents Sales Market Share Geographic Region (2020-2025)
Table 28. Global Immune Checkpoint Agents Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Immune Checkpoint Agents Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Immune Checkpoint Agents Sales by Country/Region (2020-2025) & (K Units)
Table 31. Global Immune Checkpoint Agents Sales Market Share by Country/Region (2020-2025)
Table 32. Global Immune Checkpoint Agents Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Immune Checkpoint Agents Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Immune Checkpoint Agents Sales by Country (2020-2025) & (K Units)
Table 35. Americas Immune Checkpoint Agents Sales Market Share by Country (2020-2025)
Table 36. Americas Immune Checkpoint Agents Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Immune Checkpoint Agents Sales byType (2020-2025) & (K Units)
Table 38. Americas Immune Checkpoint Agents Sales by Application (2020-2025) & (K Units)
Table 39. APAC Immune Checkpoint Agents Sales by Region (2020-2025) & (K Units)
Table 40. APAC Immune Checkpoint Agents Sales Market Share by Region (2020-2025)
Table 41. APAC Immune Checkpoint Agents Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Immune Checkpoint Agents Sales byType (2020-2025) & (K Units)
Table 43. APAC Immune Checkpoint Agents Sales by Application (2020-2025) & (K Units)
Table 44. Europe Immune Checkpoint Agents Sales by Country (2020-2025) & (K Units)
Table 45. Europe Immune Checkpoint Agents Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Immune Checkpoint Agents Sales byType (2020-2025) & (K Units)
Table 47. Europe Immune Checkpoint Agents Sales by Application (2020-2025) & (K Units)
Table 48. Middle East & Africa Immune Checkpoint Agents Sales by Country (2020-2025) & (K Units)
Table 49. Middle East & Africa Immune Checkpoint Agents Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Immune Checkpoint Agents Sales byType (2020-2025) & (K Units)
Table 51. Middle East & Africa Immune Checkpoint Agents Sales by Application (2020-2025) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Immune Checkpoint Agents
Table 53. Key Market Challenges & Risks of Immune Checkpoint Agents
Table 54. Key IndustryTrends of Immune Checkpoint Agents
Table 55. Immune Checkpoint Agents Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Immune Checkpoint Agents Distributors List
Table 58. Immune Checkpoint Agents Customer List
Table 59. Global Immune Checkpoint Agents SalesForecast by Region (2026-2031) & (K Units)
Table 60. Global Immune Checkpoint Agents RevenueForecast by Region (2026-2031) & ($ millions)
Table 61. Americas Immune Checkpoint Agents SalesForecast by Country (2026-2031) & (K Units)
Table 62. Americas Immune Checkpoint Agents Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 63. APAC Immune Checkpoint Agents SalesForecast by Region (2026-2031) & (K Units)
Table 64. APAC Immune Checkpoint Agents Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 65. Europe Immune Checkpoint Agents SalesForecast by Country (2026-2031) & (K Units)
Table 66. Europe Immune Checkpoint Agents RevenueForecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Immune Checkpoint Agents SalesForecast by Country (2026-2031) & (K Units)
Table 68. Middle East & Africa Immune Checkpoint Agents RevenueForecast by Country (2026-2031) & ($ millions)
Table 69. Global Immune Checkpoint Agents SalesForecast byType (2026-2031) & (K Units)
Table 70. Global Immune Checkpoint Agents RevenueForecast byType (2026-2031) & ($ millions)
Table 71. Global Immune Checkpoint Agents SalesForecast by Application (2026-2031) & (K Units)
Table 72. Global Immune Checkpoint Agents RevenueForecast by Application (2026-2031) & ($ millions)
Table 73. Bristol Myers Squibb Basic Information, Immune Checkpoint Agents Manufacturing Base, Sales Area and Its Competitors
Table 74. Bristol Myers Squibb Immune Checkpoint Agents Product Portfolios and Specifications
Table 75. Bristol Myers Squibb Immune Checkpoint Agents Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 76. Bristol Myers Squibb Main Business
Table 77. Bristol Myers Squibb Latest Developments
Table 78. Merck Basic Information, Immune Checkpoint Agents Manufacturing Base, Sales Area and Its Competitors
Table 79. Merck Immune Checkpoint Agents Product Portfolios and Specifications
Table 80. Merck Immune Checkpoint Agents Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 81. Merck Main Business
Table 82. Merck Latest Developments
Table 83. AstraZeneca Basic Information, Immune Checkpoint Agents Manufacturing Base, Sales Area and Its Competitors
Table 84. AstraZeneca Immune Checkpoint Agents Product Portfolios and Specifications
Table 85. AstraZeneca Immune Checkpoint Agents Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 86. AstraZeneca Main Business
Table 87. AstraZeneca Latest Developments
Table 88. Roche Basic Information, Immune Checkpoint Agents Manufacturing Base, Sales Area and Its Competitors
Table 89. Roche Immune Checkpoint Agents Product Portfolios and Specifications
Table 90. Roche Immune Checkpoint Agents Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 91. Roche Main Business
Table 92. Roche Latest Developments
LIST OFFIGURES
Figure 1. Picture of Immune Checkpoint Agents
Figure 2. Immune Checkpoint Agents Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Immune Checkpoint Agents Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Immune Checkpoint Agents Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Immune Checkpoint Agents Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Immune Checkpoint Agents Sales Market Share by Country/Region (2024)
Figure 10. Immune Checkpoint Agents Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Anti-PD-L1 Drug
Figure 12. Product Picture of Anti-PD-1 Drug
Figure 13. Product Picture of CTLA4
Figure 14. Global Immune Checkpoint Agents Sales Market Share byType in 2025
Figure 15. Global Immune Checkpoint Agents Revenue Market Share byType (2020-2025)
Figure 16. Immune Checkpoint Agents Consumed in Lung Cancer
Figure 17. Global Immune Checkpoint Agents Market: Lung Cancer (2020-2025) & (K Units)
Figure 18. Immune Checkpoint Agents Consumed in Colorectal Cancer
Figure 19. Global Immune Checkpoint Agents Market: Colorectal Cancer (2020-2025) & (K Units)
Figure 20. Immune Checkpoint Agents Consumed in BreastCancer
Figure 21. Global Immune Checkpoint Agents Market: BreastCancer (2020-2025) & (K Units)
Figure 22. Immune Checkpoint Agents Consumed in Prostate Cancer
Figure 23. Global Immune Checkpoint Agents Market: Prostate Cancer (2020-2025) & (K Units)
Figure 24. Immune Checkpoint Agents Consumed in Melanoma
Figure 25. Global Immune Checkpoint Agents Market: Melanoma (2020-2025) & (K Units)
Figure 26. Immune Checkpoint Agents Consumed in Blood Cancers
Figure 27. Global Immune Checkpoint Agents Market: Blood Cancers (2020-2025) & (K Units)
Figure 28. Global Immune Checkpoint Agents Sale Market Share by Application (2024)
Figure 29. Global Immune Checkpoint Agents Revenue Market Share by Application in 2025
Figure 30. Immune Checkpoint Agents Sales by Company in 2025 (K Units)
Figure 31. Global Immune Checkpoint Agents Sales Market Share by Company in 2025
Figure 32. Immune Checkpoint Agents Revenue by Company in 2025 ($ millions)
Figure 33. Global Immune Checkpoint Agents Revenue Market Share by Company in 2025
Figure 34. Global Immune Checkpoint Agents Sales Market Share by Geographic Region (2020-2025)
Figure 35. Global Immune Checkpoint Agents Revenue Market Share by Geographic Region in 2025
Figure 36. Americas Immune Checkpoint Agents Sales 2020-2025 (K Units)
Figure 37. Americas Immune Checkpoint Agents Revenue 2020-2025 ($ millions)
Figure 38. APAC Immune Checkpoint Agents Sales 2020-2025 (K Units)
Figure 39. APAC Immune Checkpoint Agents Revenue 2020-2025 ($ millions)
Figure 40. Europe Immune Checkpoint Agents Sales 2020-2025 (K Units)
Figure 41. Europe Immune Checkpoint Agents Revenue 2020-2025 ($ millions)
Figure 42. Middle East & Africa Immune Checkpoint Agents Sales 2020-2025 (K Units)
Figure 43. Middle East & Africa Immune Checkpoint Agents Revenue 2020-2025 ($ millions)
Figure 44. Americas Immune Checkpoint Agents Sales Market Share by Country in 2025
Figure 45. Americas Immune Checkpoint Agents Revenue Market Share by Country (2020-2025)
Figure 46. Americas Immune Checkpoint Agents Sales Market Share byType (2020-2025)
Figure 47. Americas Immune Checkpoint Agents Sales Market Share by Application (2020-2025)
Figure 48. United States Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 49. Canada Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 50. Mexico Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 51. Brazil Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 52. APAC Immune Checkpoint Agents Sales Market Share by Region in 2025
Figure 53. APAC Immune Checkpoint Agents Revenue Market Share by Region (2020-2025)
Figure 54. APAC Immune Checkpoint Agents Sales Market Share byType (2020-2025)
Figure 55. APAC Immune Checkpoint Agents Sales Market Share by Application (2020-2025)
Figure 56. China Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 57. Japan Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 58. South Korea Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 59. Southeast Asia Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 60. India Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 61. Australia Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 62. ChinaTaiwan Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 63. Europe Immune Checkpoint Agents Sales Market Share by Country in 2025
Figure 64. Europe Immune Checkpoint Agents Revenue Market Share by Country (2020-2025)
Figure 65. Europe Immune Checkpoint Agents Sales Market Share byType (2020-2025)
Figure 66. Europe Immune Checkpoint Agents Sales Market Share by Application (2020-2025)
Figure 67. Germany Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 68.France Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 69. UK Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 70. Italy Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 71. Russia Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 72. Middle East & Africa Immune Checkpoint Agents Sales Market Share by Country (2020-2025)
Figure 73. Middle East & Africa Immune Checkpoint Agents Sales Market Share byType (2020-2025)
Figure 74. Middle East & Africa Immune Checkpoint Agents Sales Market Share by Application (2020-2025)
Figure 75. Egypt Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 76. South Africa Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 77. Israel Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 78.Turkey Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 79. GCC Countries Immune Checkpoint Agents Revenue Growth 2020-2025 ($ millions)
Figure 80. Manufacturing Cost Structure Analysis of Immune Checkpoint Agents in 2025
Figure 81. Manufacturing Process Analysis of Immune Checkpoint Agents
Figure 82. Industry Chain Structure of Immune Checkpoint Agents
Figure 83. Channels of Distribution
Figure 84. Global Immune Checkpoint Agents Sales MarketForecast by Region (2026-2031)
Figure 85. Global Immune Checkpoint Agents Revenue Market ShareForecast by Region (2026-2031)
Figure 86. Global Immune Checkpoint Agents Sales Market ShareForecast byType (2026-2031)
Figure 87. Global Immune Checkpoint Agents Revenue Market ShareForecast byType (2026-2031)
Figure 88. Global Immune Checkpoint Agents Sales Market ShareForecast by Application (2026-2031)
Figure 89. Global Immune Checkpoint Agents Revenue Market ShareForecast by Application (2026-2031)
